Biotech | September 22, 2022
Charsire's new drug aims to capture dementia treatment market
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The ANDA was filed as 'First to File' submission on NCE-1 date.
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
Subscribe To Our Newsletter & Stay Updated
